Outcomes after Bone Marrow Versus Peripheral Blood Mismatched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis
Key Points
Bone marrow and peripheral blood transplantation show comparable outcomes when using posttransplant cyclophosphamide for GVHD prevention.
The key metric indicates overall survival rates are similar between the two donor types after transplantation.
Analysis of transplant results in a cohort reveals critical insights into mismatched donor procedures and their effectiveness.
Findings support the use of either bone marrow or peripheral blood while highlighting the importance of GVHD management.
Outcomes after Bone Marrow Versus Peripheral Blood Mismatched Unrelated Donor Hematopoietic Cell Transplantation Using Posttransplant Cyclophosphamide-Based GVHD Prophylaxis | Synapse